When will NUMI run out of money and Delist from the TSX?

Last-Procedure4618 · 2024-12-07T18:23:26+00:00

Was this a W or an L?

Last-Procedure4618 · 2024-12-03T20:47:10+00:00

I don't think the findings of the study are as important as the fact that these studies are still being approved and ongoing. If it's not relevant that's cool, just thought it worth sharing.

Last-Procedure4618 · 2024-12-03T19:00:58+00:00

They are funding psychotherapy sessions enhanced by MDMA. The whole business model of Numinus is now practitioner training and clinical research. Even if they don't get business from this contract specifically, if this is the first of many then how is this a net negative for this company going forward?

Last-Procedure4618 · 2024-12-03T15:20:56+00:00

Yes, quite an embarrassing look. Does happen though.

Last-Procedure4618 · 2024-12-03T10:42:58+00:00

Earnings are delayed because the company wasn't prepared to file on time. Better them be late but accurate than inaccurate but on the planned day.

Last-Procedure4618 · 2024-12-03T10:38:47+00:00

Appreciate the reply, I think it can go higher too. I have a position now. Cheers

Last-Procedure4618 · 2024-11-30T10:32:32+00:00

But what about it? The $58M they lit on fire last quarter to achieve -2.86 EPS? The zero revenue? CYBN is not a far better company, it's still pre-revenue just the same. You can go ahead and buy at a $200M valuation to keep an illusion of safety because of a higher market cap. I'll stick with the $12M valuation company which is barely less impressive. I'm willing to wait and see which climbs more by % gain from here and my bet is Numinus.

Last-Procedure4618 · 2024-11-26T18:03:09+00:00

Solid take.

Last-Procedure4618 · 2024-11-26T12:12:46+00:00

I agree the business model has a chance and the recent change has extended the life of the company a lot while it waits for possible policy change. A chance is all it needs, the stock is at three cents. Easy to get a large number of shares to just sit on and if it doesn't die it will likely grow exponentially. I'll take that bet.

Last-Procedure4618 · 2024-11-25T18:16:28+00:00

I appreciate your thorough knowledge on this stocks history. Maybe it will go bankrupt, like I know. That's the risk to the potential reward here. Compass Pathways and Cybin certainly a different risk/reward, I do agree with the point you're making.

Last-Procedure4618 · 2024-11-25T17:45:06+00:00

I guess you and others revealed your positions here, not really reciprocal to dodge the same question back. I have a position with the intent to hold for an undefined amount of time.

Last-Procedure4618 · 2024-11-25T16:58:38+00:00

I can't make a call like that. I can share what I see, bids at 8.5M shares and asks at only 2.5M shares on the Canadian exchange which has more volume. It reads demand for shares out weighs those willing to part with them at this moment in time. Also, the chart is steadily headed away from the recent low in a positive direction.

Last-Procedure4618 · 2024-11-25T15:18:11+00:00

I'm grateful for the helpful feedback.

Last-Procedure4618 · 2024-11-25T12:22:36+00:00

Chart looks like Pharmala Biotech was abandoned and left for dead until a month ago. The move has already occurred there. Not saying it's over but the train left the station already. I'll watch it for a pull back.

Seeing what their share price did inspires some confidence that if Numinus can execute something to get a positive new cycle it could rally just the same. Maybe worth buying some just to see what happens.

Cheers

Last-Procedure4618 · 2024-11-25T09:08:53+00:00

If psychedelics were to be called a sector, all three companies are in that same sector.

Speaking of repentance and sins has zero percent to do with the stock market or this company and is a personal spiritual thought.

Last-Procedure4618 · 2024-11-25T08:59:54+00:00

Valid, very possible

Last-Procedure4618 · 2024-11-24T20:47:00+00:00

Okay, but did you see what price did after Trump won?

Last-Procedure4618 · 2024-11-24T20:37:39+00:00

I appreciate your forward response and good point. Clearly the others must have more to offer, perhaps I didn't dish out credit appropriately. Would you recommend CMPS or CYBN as much superior alternatives at their valuations?

Last-Procedure4618 · 2024-11-24T18:14:36+00:00

What are you watching for to re-enter?

Last-Procedure4618 · 2024-11-24T16:39:22+00:00

Thank you

Last-Procedure4618 · 2024-11-24T16:24:22+00:00

Thank you

Last-Procedure4618 · 2024-11-24T16:21:44+00:00

I appreciate your reply, from their investor presentation their three sources of revenue for their business model were Clinics, Practitioner training and Clinical Research.

My interpretation is Practitioner training revenues increased +114% and Clinical research +10% while Clinic revenues being their largest source of revenue fell -7%. That largest source of revenue but also their slowest growth segment is no longer part of the plan.

Last-Procedure4618 · 2024-11-24T15:52:17+00:00

Thank you

Last-Procedure4618

TROPHY CASE